Jointown Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Jointown Pharmaceutical Group has a total shareholder equity of CN¥32.8B and total debt of CN¥14.1B, which brings its debt-to-equity ratio to 43.1%. Its total assets and total liabilities are CN¥101.0B and CN¥68.2B respectively. Jointown Pharmaceutical Group's EBIT is CN¥4.1B making its interest coverage ratio 4.1. It has cash and short-term investments of CN¥16.2B.
Key information
43.1%
Debt to equity ratio
CN¥14.14b
Debt
| Interest coverage ratio | 4.1x |
| Cash | CN¥16.24b |
| Equity | CN¥32.81b |
| Total liabilities | CN¥68.21b |
| Total assets | CN¥101.02b |
Recent financial health updates
We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt
Nov 17
These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well
Aug 01Recent updates
We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt
Nov 17Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss
Aug 29Earnings Working Against Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Share Price
Aug 26These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well
Aug 01Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward
Jun 07Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors
May 21Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)
Apr 05Financial Position Analysis
Short Term Liabilities: 600998's short term assets (CN¥83.1B) exceed its short term liabilities (CN¥65.7B).
Long Term Liabilities: 600998's short term assets (CN¥83.1B) exceed its long term liabilities (CN¥2.5B).
Debt to Equity History and Analysis
Debt Level: 600998 has more cash than its total debt.
Reducing Debt: 600998's debt to equity ratio has reduced from 87.6% to 43.1% over the past 5 years.
Debt Coverage: 600998's debt is not well covered by operating cash flow (9.1%).
Interest Coverage: 600998's interest payments on its debt are well covered by EBIT (4.1x coverage).